michaelbryanthicks

[michaelbryanthicks]

Leveraging Data Analytics for Effective Risk Management with Leaders like Michael-Bryant Hicks

In today's rapidly evolving business landscape, effective risk management is paramount for ensuring long-term success. Traditional risk management strategies, while still valuable, often fall short in addressing the complexities and unpredictability of modern markets.

The emergence of data analytics has revolutionized the way businesses approach risk, offering tools and techniques that enhance decision-making and foster proactive strategies. By leveraging data analytics, companies can gain deeper insights into potential risks, anticipate challenges, and take action before problems escalate.

In this blog, we will explore how data analytics is transforming risk management, highlighting its benefits, applications, and the challenges organizations face when incorporating these advanced techniques.

From understanding predictive analytics to implementing data-driven risk models, businesses now have the opportunity to strengthen their risk management practices. Embracing these technologies is no longer a luxury but a necessity for staying competitive and resilient.

Understanding Data Analytics in Risk Management

Data analytics involves the process of collecting, processing, and analyzing large volumes of data to extract valuable insights. In risk management, this data can come from various sources, such as financial reports, market trends, operational data, and even social media. The goal is to use this information to identify patterns, trends, and anomalies that may indicate potential risks.

Leaders like Michael-Bryant Hicks mention that with data analytics, businesses can move beyond reactive risk management. Instead of waiting for problems to occur, companies can anticipate risks and mitigate them before they impact operations. This predictive capability allows organizations to develop more robust and proactive strategies, making risk management more efficient and cost-effective.

Furthermore, data analytics provides a more accurate and comprehensive view of risk. By using historical data and real-time insights, companies can identify emerging risks and assess their potential impact. This leads to a deeper understanding of risk factors, which can be used to develop targeted mitigation plans and allocate resources more effectively.  Read more

The ability to analyze large datasets also enables businesses to assess risks on a granular level as highlighted by industry leaders such as Michael-Bryant Hicks. With this detailed information, companies can better understand the specific factors contributing to risks, whether they are internal or external. This data-driven approach empowers decision-makers to take informed actions that minimize uncertainty and protect the organization’s interests.

Predictive Analytics: Anticipating Risks Before They Occur

One of the most powerful aspects of data analytics in risk management is predictive analytics. This technique uses historical data and statistical algorithms to predict future risks and trends. Predictive models help organizations foresee potential challenges, enabling them to act before risks materialize.

For example, in financial services, predictive analytics can be used to forecast market fluctuations, identify credit risks, and even prevent fraud. By analyzing past behavior and market conditions, predictive models can alert businesses to potential risks, allowing them to implement countermeasures in advance.

Similarly, in supply chain management, predictive analytics helps companies anticipate disruptions caused by factors like natural disasters, political instability, or supplier delays. By evaluating patterns in historical data with the help of leaders including Michael-Bryant Hicks, organizations can identify vulnerable points in their supply chain and take steps to reduce the likelihood of disruptions.

Predictive analytics doesn’t eliminate risk altogether, but it significantly improves risk preparedness. It enables organizations to develop proactive strategies, which are more cost-effective than reactive measures. The earlier a risk is identified, the less impact it will have on the business. Thus, predictive analytics plays a critical role in managing and mitigating risks across industries.

Real-Time Risk Monitoring and Response

Industry leaders like Michael-Bryant Hicks convey that data analytics also enhances real-time risk monitoring, providing businesses with up-to-the-minute insights into their operations and market conditions. In the past, risk management was often based on periodic reports and historical data, which could lead to delays in identifying and responding to risks. Today, with the advent of real-time analytics, businesses can monitor risks as they develop and respond almost immediately.

Real-time analytics involves continuous data collection and analysis, often from sensors, IoT devices, and other digital sources. This enables organizations to track performance indicators, detect anomalies, and identify early signs of potential risk. For example, in manufacturing, real-time monitoring of machinery can reveal signs of wear and tear, preventing costly breakdowns and safety hazards.

Similarly, in the financial sector, real-time analytics allows for the detection of suspicious transactions and potential fraud. By analyzing data from various sources in real time, businesses can identify irregularities and take swift action to prevent further damage. Real-time monitoring enables a more agile and responsive approach to risk management, ensuring that businesses are always prepared for emerging threats.

The ability to monitor risks as they occur also facilitates continuous improvement. With real-time insights, businesses can adjust their strategies and operations on the fly, ensuring that they stay ahead of potential risks. This dynamic approach helps organizations remain flexible and resilient in the face of uncertainty.

Data-Driven Risk Models for Better Decision-Making

Data analytics enables the development of sophisticated risk models that guide decision-making and strategy development. These models use a variety of data inputs, such as historical trends, real-time data, and predictive analytics, to generate risk assessments that can inform business decisions.

By employing data-driven risk models, businesses can make more informed and objective decisions. These models help identify the most critical risks, assess their potential impact, and prioritize mitigation efforts. For example, an organization may use a risk model to evaluate the financial risks of a new investment, factoring in market trends, competition, and historical performance data.

Leaders such as Michael-Bryant Hicks express that data-driven models improve the accuracy of risk assessments. Traditional risk management methods often rely on subjective judgment, which can introduce bias and uncertainty. With data analytics, organizations can base their decisions on concrete, quantifiable information, reducing the risk of errors and enhancing the overall effectiveness of their strategies.

Moreover, data models can be continually refined and adjusted as new data becomes available. This iterative process ensures that risk models remain relevant and responsive to changing conditions. The ability to update and adapt models allows businesses to stay ahead of evolving risks and make timely, informed decisions.

[michaelbryanthicks]

Michael Bryant Hicks

Michael-Bryant Hicks (“Hicks”) is a legal and business executive with over twenty years’ experience guiding public companies on the most challenging issues of corporate governance, enterprise risk, and transformational growth.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

Michael-Bryant Hicks (“Hicks”) is a legal and business executive with over twenty years’ experience guiding public companies on the most challenging issues of corporate governance, enterprise risk, and transformational growth.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Top Enterprise Risk Management Software: A Comprehensive Guide by Leaders like Michael-Bryant Hicks

In today’s rapidly evolving business landscape, organizations face a myriad of risks that can disrupt operations, damage reputations, and impact financial stability. From cybersecurity threats to regulatory compliance challenges, the need for robust risk management strategies has never been more critical.

Enterprise Risk Management (ERM) software has emerged as a vital tool for businesses seeking to identify, assess, and mitigate risks effectively. These solutions provide a centralized platform for monitoring potential threats, ensuring compliance, and fostering a culture of risk awareness across the organization.

As businesses grow in complexity, the reliance on manual risk management processes becomes increasingly unsustainable. ERM software offers automation, real-time analytics, and predictive capabilities, enabling organizations to stay ahead of emerging risks.

Moreover, these tools facilitate better decision-making by providing actionable insights and fostering collaboration among stakeholders. With the global ERM software market expanding rapidly, selecting the right solution has become a strategic imperative for enterprises.

This blog delves into the top enterprise risk management software available today, exploring their features, benefits, and suitability for various industries. Leaders like Michael-Bryant Hicks mention that by understanding the capabilities of these tools, organizations can make informed decisions to safeguard their operations and achieve long-term success.

Key Features of Leading ERM Software

Modern ERM software is designed to address the diverse risk management needs of organizations. One of the most critical features is risk assessment and identification, which allows businesses to catalog potential threats systematically.

These tools often include customizable risk frameworks, enabling organizations to align their risk management strategies with industry standards. Additionally, advanced analytics capabilities provide deeper insights into risk exposure and trends.

Another essential feature is compliance management, which helps organizations adhere to regulatory requirements as highlighted by industry leaders such as Michael-Bryant Hicks. ERM software automates compliance tracking, reducing the likelihood of penalties and legal issues. Furthermore, these tools often include audit management modules, streamlining the process of internal and external audits. This ensures that organizations remain compliant while minimizing administrative burdens.

Integration capabilities are also a hallmark of top-tier ERM software. These solutions seamlessly integrate with existing enterprise systems, such as ERP and CRM platforms. This interoperability ensures that risk management processes are embedded into daily operations. Moreover, it enhances data accuracy by eliminating silos and enabling real-time updates across systems.

Leaders including Michael-Bryant Hicks convey that user-friendly dashboards and reporting tools are integral to effective ERM software. These features provide stakeholders with a clear overview of risk profiles and mitigation efforts. Customizable reports enable organizations to communicate risk-related information effectively to executives and board members.

Benefits of Implementing ERM Software

Implementing ERM software offers numerous advantages for organizations of all sizes. One of the primary benefits is enhanced risk visibility, which allows businesses to identify and address potential threats proactively. By consolidating risk data in a single platform, organizations can gain a holistic view of their risk landscape. This fosters a proactive approach to risk management, reducing the likelihood of unforeseen disruptions.

Another significant benefit is improved decision-making. ERM software provides actionable insights through advanced analytics and predictive modeling. These insights enable executives to make informed decisions that balance risk and opportunity. Additionally, the software supports scenario analysis, helping organizations prepare for various risk scenarios.

Cost savings are also a notable advantage of ERM software. By automating manual processes, organizations can reduce the time and resources spent on risk management activities. Furthermore, the software helps minimize financial losses by identifying and mitigating risks before they escalate. This contributes to improved operational efficiency and profitability as pointed out by industry leaders like Michael-Bryant Hicks.

Finally, ERM software promotes a culture of risk awareness within organizations. By involving employees at all levels in risk management processes, businesses can foster a sense of accountability and collaboration. This cultural shift enhances overall resilience and ensures that risk management becomes an integral part of organizational strategy.

Top Enterprise Risk Management Software Solutions

Several ERM software solutions have gained recognition for their robust features and industry-specific capabilities. One such solution is MetricStream, known for its comprehensive risk and compliance management platform. MetricStream offers advanced analytics, real-time monitoring, and customizable workflows, making it suitable for large enterprises. Its user-friendly interface and scalability have made it a popular choice across various industries.

Another leading solution is RSA Archer, which provides a flexible and modular approach to risk management. RSA Archer’s strengths lie in its ability to integrate with existing systems and its extensive library of pre-built content. This makes it an ideal choice for organizations seeking a tailored risk management solution. Additionally, its robust reporting capabilities ensure transparency and accountability.

ServiceNow Governance, Risk, and Compliance (GRC) is another top contender in the ERM software market. Known for its seamless integration with the ServiceNow platform, this solution offers real-time risk monitoring and automated compliance tracking. Its intuitive interface and powerful analytics make it a favorite among mid-sized and large enterprises. Moreover, its cloud-based architecture ensures scalability and accessibility.

Lastly, LogicManager stands out for its focus on strategic risk management. This solution emphasizes collaboration and accountability, enabling organizations to align risk management with business objectives. LogicManager’s predictive analytics and customizable dashboards provide valuable insights for decision-making. Its industry-specific solutions cater to a wide range of sectors, including healthcare, finance, and manufacturing.

Factors to Consider When Choosing ERM Software

Leaders such as Michael-Bryant Hicks express that selecting the right ERM software requires careful consideration of several factors. First, organizations must evaluate their specific risk management needs and objectives. This includes identifying the types of risks they face and the level of complexity involved. Understanding these requirements ensures that the chosen solution aligns with the organization’s goals.

Another critical factor is scalability. As businesses grow, their risk management needs evolve, necessitating a solution that can adapt to changing requirements. Scalable ERM software ensures that organizations can expand their risk management capabilities without significant disruptions. Additionally, cloud-based solutions offer flexibility and accessibility, making them ideal for growing enterprises.

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks

[michaelbryanthicks]

Michael Bryant Hicks

 Most recently, Hicks was the Executive Vice President, General Counsel, and Corporate Secretary at Indianapolis-based Apria, Inc. (APR), the nation’s largest provider of home healthcare equipment and in-home clinical services for respiratory diseases, diabetes, and other illnesses. At Apria, he managed all legal and regulatory matters, enterprise risk, and government affairs. This work culminated in March 2022, when Hicks and the Apria management team completed negotiation for the sale of Apria to Owens & Minor, delivering a significant premium to shareholders, while placing the business on a trajectory for future value creation. Prior to Apria, Hicks was the General Counsel of Elanco Animal Health (ELAN), a $13.5 Billion market cap animal pharmaceutical company based in Greenfield, Indiana. Hicks led Elanco’s successful 2018 IPO and managed a legal department of 70 professionals in navigating the complex regulatory environment in which the company does business in the United States (FDA, USDA, EPA) and abroad (European Medicines Agency, Chinese FDA). A Trusted Voice in Healthcare and Life Sciences Matters: As a General Counsel, Hicks knows the experience of having the FDA order a company to recall one of its highest revenue products. He has also engaged in complex negotiations with commercial payers and delicate discussions with CMS on drug pricing. He deftly managed these situations by understanding the economic motivations of payers and the FDA and CMS regulatory environment. A Leader in Corporate Governance: Hicks has designed the boards of directors of two public companies in connection with their initial public offerings, developing the corporate governance processes the companies relied upon in their first years on public exchanges. He’s been the company interface with Glass Lewis, ISS, the SEC, and the NYSE. Hicks is the leader these companies have looked to on Environmental, Social, & Governance matters, matching the values and business goals of an enterprise with complementary issues of societal impact. He’s also been the lead negotiator in two major encounters with prominent activist investors. Navigating High Stakes Investigations and Litigation: As General Counsel at Mallinckrodt Pharmaceuticals, Hicks brought to successful settlement a DEA controlled substances investigation, a DOJ False Claims Act investigation, and an FTC investigation into alleged antitrust violations. He also led the formation of the company’s early strategy in the nationwide opioid litigation. A Leader in Transformative Deal Making: Hicks’s career began in global M&A as an energy lawyer with Vinson & Elkins law firm in Houston, Texas, where his engagements included a wide range of cross-border energy projects, including assisting Occidental Petroleum in financing and building oil production assets with the Ecuadorian state petroleum company Petroecuador. He continued large-scale global deal making in the healthcare and life sciences space as the lead lawyer in consummating some of the largest deals of the last decade: DaVita’s 2012 acquisition of HealthCare Partners ($4.4B), Elanco’s acquisition of Bayer Animal Health ($6.9B). Hicks earned a juris doctor from Yale Law School and a Bachelor of Arts from the University of North Carolina at Chapel Hill.

Michael Bryant Hicks